1621. Novel Beta-lactam Beta-lactamase Inhibitors Against Alternative Antibiotics for the Treatment of Complicated Urinary Tract Infections and Pyelonephritis Caused by Carbapenem-resistant Enterobacterales

BACKGROUND: There is little data on the comparative efficacy or safety of carbapenem-resistant Enterobacterales (CRE)-targeted beta-lactam beta-lactamase inhibitors (BL-BLI), including ceftazidime/avibactam (CZA) and meropenem/vaborbactam (MVB), versus alternative antibiotics for the treatment of CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Bliss, Meredith, Jacqueline, Ackley, Renee, McCarter, Maggie S, Polk, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778202/
http://dx.doi.org/10.1093/ofid/ofaa439.1801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778202/
http://dx.doi.org/10.1093/ofid/ofaa439.1801

Ejemplares similares